C12N 2740/15032
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2740/15032 (Use of virus as therapeutic agent, other than vaccine) appears on 22 US grants and 48 published applications in this corpus.
Search patents in C12N- Granted patents
- 22
- Published applications
- 48
- Assignees
- 24
- Inventors
- 86
- Latest grant
- 21 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 1 | 1 |
| 2015 | 0 | 3 |
| 2016 | 2 | 5 |
| 2017 | 1 | 4 |
| 2018 | 3 | 2 |
| 2019 | 1 | 3 |
| 2020 | 1 | 3 |
| 2021 | 2 | 2 |
| 2022 | 0 | 2 |
| 2023 | 6 | 7 |
| 2024 | 0 | 4 |
| 2025 | 2 | 5 |
| 2026 | 3 | 5 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions for rejuvenating CNS glial populations by suppresion of transcription factors21 Jul 2026US 12,686,868 B2University of Rochester
- Chimeric antigen receptor targeting BCMA and use thereof9 Jun 2026US 12,649,785 B2National Cancer Center
- MicroRNA-mediated methods for rejuvenating CNS glial populations3 Mar 2026US 12,565,648 B2University of Rochester
- Compositions and methods of treatment using nicotinamide mononucleotide24 Jun 2025US 12,337,010 B2Washington University
- Viral vectors and packaging cell lines4 Feb 2025US 12,215,337 B2Umoja Biopharma, Inc.
- Materials and methods for increasing immune responses within a mammal8 Oct 2026US 2026/0306668 A1Mayo Foundation for Medical Education and Research
- Chimeric antigen receptor targeting bcma and use thereof10 Sep 2026US 2026/0265371 A1National Cancer Center
- Recombinant retrovirus, compositions, and methods of use30 Jul 2026US 2026/0218136 A1Kelonia Therapeutics, Inc.
- Lentiviral particles displaying fusion molecules and uses thereof18 Jun 2026US 2026/0166143 A1Umoja Biopharma, Inc.
- Gene sequence construct used for treatment of central nervous system diseases30 Apr 2026US 2026/0117234 A1
Most cited
By later US patents
- Pluripotent cell lines and methods of use thereof20US 8,669,048 B2Parkinson's Institute · 2014
- Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses17US 10,046,064 B2Selecta Biosciences, Inc. · 2018
- Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses17US 10,071,114 B2Selecta Biosciences, Inc. · 2018
- Nipah virus envelope pseudotyped lentiviruses and methods of their use7US 10,064,958 B2The Regents of the University of California · 2018
- Nipah virus envelope pseudotyped lentiviruses and methods of their use6US 11,576,982 B2The Regents of the University of California · 2023